Last reviewed · How we verify
placebo+chemotherapy — Competitive Intelligence Brief
phase 3
Chemotherapy enhancer
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
placebo+chemotherapy (placebo+chemotherapy) — Jiangsu HengRui Medicine Co., Ltd.. This drug works by enhancing the effects of chemotherapy.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| placebo+chemotherapy TARGET | placebo+chemotherapy | Jiangsu HengRui Medicine Co., Ltd. | phase 3 | Chemotherapy enhancer |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Chemotherapy enhancer class)
- Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- placebo+chemotherapy CI watch — RSS
- placebo+chemotherapy CI watch — Atom
- placebo+chemotherapy CI watch — JSON
- placebo+chemotherapy alone — RSS
- Whole Chemotherapy enhancer class — RSS
Cite this brief
Drug Landscape (2026). placebo+chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-chemotherapy. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab